Granted Patent
B2
US 12,291,549 · App. 17/320,286 · Granted May 6, 2025
Farnesoid X receptor modulators
Assignee:
Intercept Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present application provides a compound of formula I: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R 1 -R 10 , m, n, p, and are as described herein. The present invention relates generally to FXR modulators and to methods of making and using said compounds.
Claims (2)
1. A compound of formula
2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable of solvate thereof, and a pharmaceutically acceptable carrier or excipient.
Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 12, 2026
From: INTERCEPT PHARMACEUTICALS, INC.
To: ALFASIGMA S.P.A
Reel/Frame 075044/0679 →
RELEASE OF SECURITY INTEREST
Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS
Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0990 →
SECURITY INTEREST
Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 27, 2021
From: PELLICCIARI, ROBERTO; GIOIELLO, ANTIMO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 056376/0631 →
Continuity (3)
Provisional Application
62238246
· Oct 7, 2015
References Cited (70)
US 2599481A
· Plattner
· 1952
[cited by applicant]
US 4514393A
· Castagnola et al.
· 1985
[cited by applicant]
US 9611289B2
· Pellicciari
· 2017
[cited by examiner]
US 20080182832A1
· Pellicciari
· 2008
[cited by examiner]
US 20100093687A1
· Song et al.
· 2010
[cited by applicant]
US 20100152151A1
· Pellicciari
· 2010
[cited by applicant]
US 20120283234A1
· Pellicciari
· 2012
[cited by applicant]
US 20220127302A1
· Pellicciari et al.
· 2022
[cited by applicant]
US 20220226350A1
· Macconell et al.
· 2022
[cited by applicant]
US 20230233581A1
· Pellicciari
· 2023
[cited by applicant]
EP 0312867
· 1989
[cited by applicant]
WO WO200275298
· 2002
[cited by applicant]
WO WO2014184271A1
· 2014
[cited by examiner]
WO WO2014184271
· 2017
[cited by applicant]
WO WO2017062763
· 2017
[cited by applicant]
WO WO2017062856
· 2017
[cited by applicant]
WO WO2017156024
· 2017
[cited by applicant]
Bidstrup, et al., “CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide”, Br J Clin. Pharmacol, 2003, 56, 305-14.
[cited by applicant]
Borgstrom E., et al. “Partial synthesis of compounds related to adrenal cortical hormones: XI. Reactions of ring c ketols in the preparation of an 11-keto bile acid”, The Journal of Biological Chemistry, 1949, vol. 177,…
[cited by applicant]
Bream et al. J. Chem. Soc. 1957, 1974-1981, 1957.
[cited by applicant]
CAPLUS record for Halperin, G. Steroids 1979, 33, 295-304, 1979.
[cited by applicant]
CAS Registry Entry for Registry No. 163976-40-7, which entered STN on Jun. 22, 1995 (Year: 1995).
[cited by applicant]
CAS Registry Entry for Registry No. 203739-20-2, which entered STN on Apr. 7, 1998 (Year: 1998).
[cited by applicant]
CAS Entry for International Application Publication No. WO 2004064521 A1 by Koga et al., 2004.
[cited by applicant]
Cree and Andreotti, “Measurement of Cytotoxicity by ATP-based Luminescence Assay in Primary Cell Cultures and Cell Lines”, Toxicology In-Vitro, 1997, 11, 553-556.
[cited by applicant]
Cronholm T., et al. “Excretion of endogenous steroids and metabolites of [4-
[cited by applicant]
Crouch et al., “The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity”, J Immunol. Methods, 1993, 160, 81-88.
[cited by applicant]
D'Amore C. et al. “Design, Synthesis, and Biological Evaluation of Potent Dual Agonists of Nuclear and Membrane Bile Acid Receptors”, Journal of Medicinal Chemistry, vol. 57, No. 3, 2014, pp. 937-954.
[cited by applicant]
Dorn et al. “Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition”, J Biomol Screen, 2005, 10, 339-347.
[cited by applicant]
Festa C. et al. “Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor (GP-BAR1) Ligands”, Journal of Medicial Chemistry, vol. 57,…
[cited by applicant]
GenBank Accession No. NM 021745, May 9, 1995.
[cited by applicant]
GenBank Accession No. NM 009108, Dec. 6, 2016.
[cited by applicant]
GenBank Accession No. NM 005123, Feb. 11, 2007.
[cited by applicant]
Gioiello, et al., “Bile Acid Derivatives as Ligands of the Farnesoid X Receptor: Molecular Determinants for Bile Acid Binding and Receptor Modulation”, 2014 Curr. Top. Med. Chem. 14, 2159.
[cited by applicant]
Heery, et al., “A signature motif in transcriptional co-activators mediates binding to nuclear receptors”, Nature, 1997, 387, 733-736.
[cited by applicant]
Huber et al., “Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters”, Gene 290:35-43 (2002).
[cited by applicant]
Ishida et al. Biol. Pharm. Bull. 1999, 22, 828-835.
[cited by applicant]
Ishida H. et al. “Study on the Bile Salts from Sunfish, Mola mola L. I. The Structures of Sodium Cyprinol Sulfates, the Sodium Salt of a New Bile Acid Conjugated with Taurine, and a New Bile Alcohol and Its New Sodium S…
[cited by applicant]
Kangas, et al., “Bioluminescence of Cellular ATP: A New Method for Evaluating Cytotoxic Agents in Vitro”, Medical Biology, 1984, 62, 338-343.
[cited by applicant]
Kawamata, et al., “AG Protein-coupled Receptor Responsive to Bile Acids”, J Biol. Chem., 2003,278, 9435-9440.
[cited by applicant]
Long W. et al. “Partial Synthesis of Compounds Related to Adrenal Cortical Hormones IX. Stepwise Degradation of the Side Chain of 3alpha,llalpha-Dihydroxycholanic Acid*”, Journal of biologica Chemistry, vol. 165, No. 1,…
[cited by applicant]
Makishima, et al., “Identification of a Nuclear Receptor for Bile Acids”, Science, 1999, 284, 162-1365.
[cited by applicant]
Maruyama, et al., “Identification of membrane-type receptor for bile acids (M-BAR)”, Biochem. Biophvs. Res. Commun., 2002, 298, 714-719.
[cited by applicant]
Nolte, et al., “Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-y”, Nature, 1998, 395, 137-143.
[cited by applicant]
Obach, et al., “The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions”, J Pharmacol. Exp. Ther., 2006, 316, 336-348.
[cited by applicant]
Onate, et al., “Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily”, Science, 1995, 270, 1354-1357.
[cited by applicant]
Parks, et al., “Bile Acids: Natural Ligands for an Orphan Nuclear Receptor”, Science, 1999, 284, 1365-1368.
[cited by applicant]
Pellicciari, et al., “Discovery of 6a-Ethyl-23(S)-methylcholic Acid (S-EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity”, J Med. Chem., 2009, 52, 7958-7961.
[cited by applicant]
Pellicciari R. et al. “Discovery of 3[alpha], 7[alpha],ll[beta]-Trihydroxy-6[alpha]-ethyl-5[beta]-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders”, J…
[cited by applicant]
Petty, et al., “Comparison of MTT and ATP-Based Assays for the Measurement of Viable Cell Number”, J Biolumin. Chemilumin., 1995, 10, 29-34.
[cited by applicant]
Pubchem, Substance Record for SID 85207872, Sep. 28, 2009, 5 pages.
[cited by applicant]
Pubchem, Substance Record for SID 236277322, Feb. 13, 2015, 7 pages.
[cited by applicant]
Rizzo, et al., “Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Famesoid X Receptor and TGR5 Agonist”, Mol. Pharm., 2010, 78, 617-630.
[cited by applicant]
SciFinder Record for Reiner et al. Monatschefte fuer Chemie 1975, 106, 1415-1428 (Year: 1975).
[cited by applicant]
Storer, et al., “Revalidation of the in vitro alkaline elution/rat hepatocyte assay for DNA damage: improved criteria for assessment of cytotoxicity and genotoxicity and results for 81 compounds”, Mutation Research, 199…
[cited by applicant]
Torchia, et al., “The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function”, Nature, 1997,387,677-684.
[cited by applicant]
Turner et al. “Steroids Derived from Bile Acids”, J. Biol. Chem. 1946, 166, 345-365, 1946.
[cited by applicant]
Vandenheuvel, F. A. “Gas-liquid chromatographic studies of reactions and structural relationships of steroids: II. Positions 3, 11, and 20 in the pregnane series”, Journal of Chromatography, 1975, vol. 103, p. 113-134.
[cited by applicant]
Vidic H. J. et al. “Microbial transformations of steroids, XV. Microbial hydroxylation of 3.alpha.-acetoxy-5.beta.-pregnane-20-carboxylic acid and of its methyl ester by Calonectria decora and Syncephalastrum racemosum”…
[cited by applicant]
Wang, et al., “SRC-1 and GRIP1 Coactivate Transcription with Hepatocyte Nuclear Factor 4”, J Biol. Chem., 1998, 273, 30847-30850.
[cited by applicant]
Zhu, et al. “Cloning and Identification of Mouse Steroid Receptor Coactivator-1 (mSRC-1 ), as a Coactivator of Peroxisome Proliferator-Activated Receptor y”, Gene Expr., 1996, 6,185-195.
[cited by applicant]